Assessment of serum interleukin-10 level in chronic hepatitis c patients treated with pegylated interferon and ribavirin

Abstract EN

Hepatitis C virus (HCV) infection is a major health problem.

Egypt has the highest prevalence worldwide.

Currently, combined pegylated interferon and ribavirin therapy is the standard treatment but the outcome is not satisfactory.

The present study aimed To assess the possible association of serum IL-10 level, SOD activity in erythrocyte lysate and plasma MDA level and response to combined interferon α-2a and ribavirin therapy in chronic HCV infection.

In (Group I) who were not responded to pegylated interferon and rebavirin combination therapy we found the level of serum IL-10 and plasma MDA still high while antioxidant enzyme SOD activity reduced.

While in (Group II) who responded to pegylated interferon and rebavirin combination therapy a circulating serum IL-10 and plasma MDA levels reduced but erythrocyte antioxidant enzyme SOD activity increased.